Incyte CEO Bill Meury acquires Vega Therapeutics for up to $2B, adding Phase 3 von Willebrand disease drug as Jakafi faces 2028 patent cliff.
Bill Meury has been in or led the C-suite of several biopharma companies that have constructed multibillion-dollar exits over the past decade: Allergan, Karuna and …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Incyte plans to buy Star Therapeutics and its Phase 3 bleeding disorder candidate.
Incyte to acquire Vega Therapeutics for $1.25 billion upfront, adding a rare bleeding disorder candidate with blockbuster…
Acquiring Vega Therapeutics, an offshoot of "hub-and-spoke" biotech Star Therapeutics, would give Incyte a medicine that’s in…
Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into…
A aquisição inclui o principal projeto da Vega, o VGA039, que modula a Proteína S para melhorar a hemostasia, aumentando…
Four months after Theravance Biopharma shut down its R&D unit, laid | Four months after Theravance Biopharma shut down its R&D…
Incyte Bets $1.25 Billion On Rare Bleeding Disorder Drug With Blockbuster Potential - Incyte (NASDAQ:INCY
Incyte to buy blood disorder drug in possibly $2B deal
Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders
Incyte compra Vega Therapeutics por até US$ 2 bi para expandir portfólio em hematologia
J&J looks to widen Imaavy’s use; $300M backs rare disease drug launch
Novartis RNA drug acquired in $12B Avidity deal notches a trial win
J&J eyes rare disease expansion for blockbuster-to-be Imaavy with trial win
